Anatomy of Our Lead Product
DUO-207: Gemcitabine Paclitaxel Nanoparticles
Duo Oncology is developing DUO-207 for multiple tumor types and for use in combination with immune checkpoint therapies.
DUO-207 (light blue) halts the growth of human derived tumors that remain unchecked by standard of care (dark blue). Negative control shown in red.
DUO-207 is formed from patent protected block co-polymer prodrug conjugates that self assemble into ultra-small particles, 10x smaller that current liposomal or albumin nanoparticles.
DUO-207 uses hydrogen bonding at its interfaces to facilitate the formation of ultrasmall, stable nanoparticles with high drug loading capacity.
DUO-207's particles enter a tumor through its leaky vasculature and travel between cancer cells
Cancer killing drug combination awakens immune cells within the tumor's protected microenvironment